Centering discussion on a patient profile of HER2+ gastric cancer, experts in oncology discuss the occurrence of neutropenia with trastuzumab deruxtecan therapy.
Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET
The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.
ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment
Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.
Maintenance OSE2101 With Chemo Reaches Primary OS End Point in PDAC
Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.
Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses
Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.
Mobile App May Be Feasible for Tracking Oral Cancer Medication Adherence
Although participants in the study had greater rates of nonadherence postintervention, those who reported nonadherence at baseline saw some increase in adherence.
OS Benefit With T-DXd in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma
T-DXd delivered an OS benefit for patients with unresectable or metastatic HER2-positive gastric and GEJ adenocarcinoma following trastuzumab-based treatment.
Becoming Familiar With Patients’ AEs is Essential, Says Expert
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC
Tivozanib Combo Yields Similar PROs to Monotherapy in Advanced Clear Cell RCC
Dose Reductions Possible for Tivozanib With and Without Nivolumab for RCC